Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Bucha Bio is a private U.S. biomaterials company developing sustainable materials from bacterial nanocellulose and other biobased components. The company is focused on replacing conventional leather, plastics, latex, vinyl, epoxy, and related fossil- or animal-derived materials with renewable alternatives for fashion, home goods, electronics, and automotive applications. Its first named material, SHORAI, is positioned as a high-performance textile or composite produced through fermentation-based processes. Bucha Bio appears to operate as a platform materials company rather than a therapeutics developer, with emphasis on scalable manufacturing, melt extrusion, and integration into existing industrial supply chains.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Bucha Bio.